Loading provider…
Loading provider…
Infectious Disease Physician in Rochester, NY
NPI: 1396778155Primary Employer
Infectious Disease Clinical
urmc.rochester.edu
HQ Phone
Get MD Michael's Phone Numberphone_androidMobile
Get MD Michael's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNY State Medical License
Strong Memorial Hospital of the University of Rochester
fellowship • Infectious Disease
1987 - 1990
A Highly Potent and Broadly Neutralizing H1 Influenza-Specific Human Monoclonal Antibody.
Authors: Spyros Kalams, Kenneth Mayer, Ian Frank, Hyman Scott, Margaret Mcelrath, Lindsey Baden
Journal: J Infect Dis
Authors: Alio, Amina P, Fields, Sheldon D, Humes, Damon L, Bunce, Catherine A, Wallace, Stephaun E, Lewis, Cindi, Elder, Heather, Wakefield, Steven, Keefer, Michael C
Journal: J Gay Lesbian Soc Serv
Lead Sponsor: Sanofi Pasteur, a Sanofi Company
Collaborators: GlaxoSmithKline
Intervention / Treatment: BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03, BIOLOGICAL: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1, BIOLOGICAL: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2, BIOLOGICAL: SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3, BIOLOGICAL: SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4